| 李鲁杨,任国华,刘向红.扶正降黏胶囊改善冠心病患者血栓前期相关因素的临床研究[J].,2005,(8):691-695 |
| 扶正降黏胶囊改善冠心病患者血栓前期相关因素的临床研究 |
| Clinical Study of Fuzheng Jiangnian Capsule in Improving Pre-thrombosis Correlated Factors in Patients with Coronary Heart Disease |
| |
| DOI： |
| 中文关键词: 扶正降黏胶囊 冠心病 血栓前期相关因素 |
| 英文关键词:Fuzheng Jiangnian Capsule coronary heart disease pre-thrombosis correlated factors |
| 基金项目:山东省科技厅计划攻关课题(No.991205708) |
|
| Hits: 1320 |
| Download times: 1305 |
| 中文摘要: |
| 目的探讨扶正降黏胶囊对冠心病患者血栓形成前期相关因素的影响。方法将90例冠心病合并高黏滞血症患者随机分为3组,在常规治疗基础上分别加用健脾补肾活血药扶正降黏胶囊(FZJN组,30例)、活血化瘀药复方丹参滴丸(DSDW组,30例)及阿司匹林(ASP组,30例)治疗2个月。观察3组患者的临床疗效及治疗前后内皮素(ET)、一氧化氮(NO)、凝血因子I(Fib)、D-二聚体(DD)、血小板颗粒膜糖蛋白(CD62p)、超氧化物歧化酶(SOD)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)水平,并与健康对照组(30名)作比较。结果与健康对照组比较,冠心病患者的Fib、DD、ET、CD62p均明显升高,NO、SOD均明显降低(P<0·05,P<0·01);与本组治疗前比较,治疗后FZJN组的Fib、DD、ET、CD62p、LDL-C显著下降,NO、SOD显著升高(P<0·05,P<0·01);DSDW组的ET、CD62p显著下降,SOD明显升高(P<0·05);ASP组CD62p显著下降(P<0·05),DD、ET虽有改善,但差异无显著性;3组冠心病患者的中医证候总有效率、心绞痛总有效率、硝酸酯类药物停减率,FZJN组优于DSDW组、ASP组(P<0·05);心电图改善率FZJN组、DSDW组优于ASP组(P<0·05)。结论冠心病患者血栓形成前期可见Fib、DD、ET、CD62p升高,NO、SOD下降;与阿司匹林比较,复方中药可多途径、多环节的作用于冠心病患者血栓形成前状态;在改善相关血液分子标志物和临床证候等方面,扶正降黏胶囊优于复方丹参滴丸;提示扶正降黏胶囊的作用机理可能与扩张血管、改善微循环、减轻血管内皮细胞损伤、抑制血小板活化、调整凝血-纤溶平衡、改善自由基代谢及降低低密度脂蛋白水平有关。 |
| 英文摘要: |
| ObjectiveTo explore the effect of Fuzheng Jiangnian Capsule (FZJN) on the pre-thrombosis correlated factors in patients with coronary heart disease (CHD). MethodsNinety patients with CHD complicated with blood hyperviscosity syndrome were treated with conventional treatment and randomly divided into three groups by the additional treatment, i.e. the FZJN group (FZJN, a preparation with action of invigorating Pi, supplementing Shen, and activating blood circulation), the CSDP group 〔Compound Salviae droplet pill , CSDP) with the action of activating blood circulation to remove blood stasis〕 and the aspirin (ASP) group, 30 patients in each group. After two months of treatment, clinical efficacy, the levels of endothelin (ET), nitric oxide (NO), coagulation factor I (Fib), D-dimer (DD), thrombocytic granule membranous glucoprotein (CD62p), superoxide dismutase (SOD), high- and low-density lipoprotein-cholesterol (HDL-C, LDL-C) in patients before and after treatment were observed and compared with those in the healthy control group. ResultsCompared with the healthy control group, the levels of Fib, DD, ET, CD62p were significantly higher, NO and SOD significantly lower (<0.05, <0.01) in all the patients with CHD. Compared with the same group before treatment, the levels of Fib, DD, ET, CD62p, LDL-C in the FZJN group lowered significantly, while NO and SOD raised significantly (<0.05, <0.01). ET and CD62p in the CSDP group lowered significantly, while SOD raised significantly (W<0.05), CD62p in the ASP group lowered significantly (P<0.05). No statistical difference was found in comparison of DD or ET, though certain improvement was shown. The total effective rate in relieving TCM syndromes and angina pectoris, and the decrease or stop rate of nitrate esters medication were superior in FZJN group to those in the CSDP group and the ASP group, respectively (<0.05). The rate of electrocardiogram improvement in the FZJN and CSDP group was superior to that in the ASP group (<0.05). ConclusionIncrease of Fib, DD, ET, CD62p, and decrease of NO and SOD levels were found in patients with CHD in prethrombosis stage. Compared with ASP, compound Chinese medicinal herbs can act on the prethrombosis manner of CHD patients through multi-paths, multi-links. FZJN showed better efficacy in improving correlated blood molecule markers and clinical syndromes than CSDP, suggesting that the possible mechanism of FZJN might be related to its actions in dilating blood vessels, improving microcirculation, alleviating endothelial cell damage, inhibiting activity of blood platelet, regulating coagulation-fibrolysis balance, improving metabolism of free radicals as well as lowering the level of LDL-C. |
| View Full Text View/Add Comment Download reader |
|
|
|
